At a Glance : While standard antidepressants can take weeks to show effects, ketamine may reduce suicidal ideation in as little as 40 minutes. This rapid response is crucial during acute crises. The FDA’s approval of Spravato for major depressive disorder with acute suicidal thoughts represents a significant advancement in psychiatric care. If you or a loved one have struggled with persistent suicidal thoughts and conventional methods haven’t helped, exploring ketamine treatment could be an essential step in your healing journey. Read this to see how it works!
I want to start this one by naming something that often goes unsaid in how psychiatry talks about crisis care.
Standard antidepressants take four to six weeks to work. Sometimes longer. For someone in the grips of active suicidal ideation — not passive thoughts, but real intent — that timeline is not a clinical inconvenience. It is a dangerous gap. We ask people in genuine crisis to wait for medication that might help them in six weeks, while the window of acute danger is right now.
Ketamine doesn’t work like that. And understanding why matters for anyone who is suffering acutely, or who loves someone who is.
In 2019, the FDA approved Spravato (esketamine) — an intranasal ketamine formulation — for treatment-resistant depression. In 2020, it received an additional approval for major depressive disorder with acute suicidal ideation or behavior (MDD-SI).
That second approval is remarkable. The FDA approved a treatment specifically for active suicidal ideation — a category where almost nothing else has a direct indication. The bar for that approval requires evidence that the treatment actually reduces acute suicidal risk, not just depression in general. Spravato cleared it.
This doesn’t mean Spravato is a complete solution to suicidal crisis on its own. The approval specifies use alongside standard-of-care treatment. But it does mean the evidence crossed a regulatory threshold that no antidepressant before it has for this specific indication.
This is the question that matters most when someone is in danger. The answer, documented across multiple trials, is striking.
A 2018 NIH study found that a single IV ketamine infusion produced significant reductions in suicidal ideation within 40 minutes of administration — before any meaningful antidepressant effect had even developed. This is important: the anti-suicidal effect appears to be at least partially independent of the antidepressant effect. Something specific is happening in the neurobiology of suicidal ideation that ketamine addresses directly and fast.
Subsequent studies have replicated rapid reductions in suicidal ideation following both IV ketamine and intranasal esketamine, with effects often detectable within hours and clinically meaningful improvements within one to three days.
For context: starting sertraline or escitalopram today means waiting four to six weeks to know if it’s working. A ketamine infusion today means something may shift by this evening.
Suicidal ideation in the context of severe depression involves several neurological patterns that converge in dangerous ways: hyperactivity in the default mode network (the brain’s self-referential, rumination machine), reduced connectivity between the prefrontal cortex and the regions that govern impulse control and future-oriented thinking, and a narrowing of psychological perspective that makes the current suffering feel permanent and inescapable.
Ketamine interrupts these patterns rapidly. The NMDA receptor blockade reduces the hyperactive rumination circuitry. The rapid synaptogenesis restores prefrontal connectivity. And the dissociative experience itself — the loosening of the ordinary ego and its suffering — appears to produce a perceptual shift in the acuity and permanence of pain that can be genuinely therapeutic in the short term.
This isn’t a sedative effect. Benzodiazepines sedate. Ketamine restructures — and it does it fast.
If you are currently experiencing suicidal ideation, please call 988 (the Suicide and Crisis Lifeline) or go to your nearest emergency room if you are in immediate danger. This post is not a substitute for acute crisis care.
But if you or someone you love has been in and out of a psychiatric crisis cycle — improving briefly, declining again, going back to the ER or inpatient care — and the underlying depression has not responded to multiple antidepressant trials, this is the conversation to have. Ketamine, and specifically Spravato for insured patients, offers a mechanism of action and a speed of response that nothing in the standard antidepressant toolbox can match.
At our Cardiff and Newport Beach clinics, we evaluate patients with histories of suicidal ideation carefully and honestly. We don’t use crisis presentations as a sales opportunity. If we think ketamine is appropriate for your situation, we’ll tell you why. If we think a different level of care is needed first, we’ll tell you that too.
Spravato (esketamine) — the intranasal formulation — has FDA approval specifically for major depressive disorder with acute suicidal ideation or behavior. That’s an explicit regulatory indication, not an off-label use. IV ketamine doesn’t carry that specific FDA label, but the clinical evidence for rapid anti-suicidal effects is substantial and has been replicated across multiple studies. The FDA approval matters for insurance coverage and for signaling that the evidence for Spravato cleared a very high regulatory bar for this specific use case.
If someone is in immediate danger — expressing intent, has a plan, or has means available — call 988 or go to the ER first. That’s not us deflecting; that’s the honest appropriate response to acute crisis. Where Seaside Ketamine becomes relevant is in the period after acute stabilization, or for patients who are in a chronic cycle of suicidal ideation that has not responded to standard antidepressants and ongoing psychiatric care. That’s the gap ketamine is specifically positioned to address. Call us once the immediate safety is managed and we’ll talk through what a thoughtful next step looks like.
Yes, both locations are certified Spravato treatment sites. For patients with the MDD-SI indication, Spravato has a specific insurance pathway — generally the same prior authorization process as the TRD indication, with documentation of the acute suicidal ideation as part of the clinical record. Coverage varies by plan, but most major commercial insurers, Medicare, and Medi-Cal have established Spravato coverage. We assist with verification and prior authorization before beginning treatment. Call either location directly and we’ll walk you through it.
